1. Home
  2. RDHL vs BDRX Comparison

RDHL vs BDRX Comparison

Compare RDHL & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

HOLD

Current Price

$1.13

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Logo Biodexa Pharmaceuticals plc

BDRX

Biodexa Pharmaceuticals plc

HOLD

Current Price

$2.62

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDHL
BDRX
Founded
2009
2000
Country
Israel
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8M
4.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RDHL
BDRX
Price
$1.13
$2.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
66.1K
2.8M
Earning Date
09-05-2025
09-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,550,000.00
N/A
Revenue This Year
$381.91
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
157.62
N/A
52 Week Low
$1.01
$2.55
52 Week High
$7.00
$92.00

Technical Indicators

Market Signals
Indicator
RDHL
BDRX
Relative Strength Index (RSI) 44.31 38.99
Support Level $1.10 $4.55
Resistance Level $1.23 $7.22
Average True Range (ATR) 0.05 1.49
MACD 0.00 -0.28
Stochastic Oscillator 28.25 1.25

Price Performance

Historical Comparison
RDHL
BDRX

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

About BDRX Biodexa Pharmaceuticals plc

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

Share on Social Networks: